A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
A phase 1/2 trial of HS-10566 in bladder & urothelial cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.
Overview
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy is a phase 1/2 interventional study registered as NCT07468851 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 180 participants planned, started 2026-08-05 and due to reach its primary completion in 2028-04-30. Interventions recorded: HS-10566.
Similar pages
not linked directly; found by shared links- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialSafety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Shares Bladder & urothelial cancer and the tag pipeline.